Prosthesis type has minimal impact on survival after valve surgery in patients with moderate to end-stage renal failure

Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA.
Nephrology Dialysis Transplantation (Impact Factor: 3.58). 08/2008; 23(11):3613-21. DOI: 10.1093/ndt/gfn337
Source: PubMed


Few previous studies have reported on the outcome of patients with renal failure (RF) undergoing valvular surgery, particularly with regard to choice of valve prosthesis.
We retrospectively analyzed prospectively collected data from 155 patients with RF (mean age 62 +/- 14, 42% female) who underwent left-sided valve surgery from January 1998 to December 2006. Patients were divided into two groups: Group 1 (non-dialysis-dependent renal failure (NDRF); creatinine >2.5 mg/dl; n = 47, 40%) and Group 2 (renal failure dialysis (DRF); n = 108, 60%). Mechanical valves were implanted in 50 (32%) patients and bioprostheses in 63 (41%). Isolated mitral valve reconstruction was performed in 27% (n = 42) of patients. Outcome measures included hospital mortality, major postoperative complications, length of hospital stay, discharge planning and late survival.
The overall hospital mortality was 19.3% (n = 30) and was not different between Groups 1 (23%) and 2 (18%). Ejection fraction, peripheral vascular disease, aortic valve replacement and reoperation were independent predictors of hospital mortality. One- and five-year survival rates were 74.4 +/- 7.8% and 53.1 +/- 10.1% in Group 1 and 75.8 +/- 4.6% and 49.1 +/- 7.1% in Group 2 (P = ns), respectively. According to the type of prostheses, hospital mortality and freedom from reoperation were similar in patients with mechanical and biological valves. Five-year survival rate was 51 +/- 10.7 for biological valves versus 55 +/- 8.4 for mechanical valves (P = ns).
Hospital mortality and morbidity remain high in patients with RF undergoing valvular surgery and it is not different in NDRF and DRF patients. This study suggests that the type of valve prosthesis does not appear to have an impact on early and late survival but is limited by sample size. It may be that bioprostheses should be more widely used in patients with RF requiring valve replacement.

Download full-text


Available from: Joseph A Vassalotti, Mar 04, 2014
  • Source
    • "This low survival rate can be explained by the fact that they studied patients over 2 decades (from 1978 to 1998), during which a great improvement in the quality and availability of medical services has been achieved leading to improvement of the survival. Later studies reported better 5-year survival, improving with time and ranging from 31 to 49%[23,24]. Thourani et al. reported a longer follow-up, with a 10-year adjusted survival of 18.1% regardless the type of the valve implanted. "
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES End-stage renal disease patients on regular haemodialysis are at higher risk of calcification. Therefore, many surgeons have concerns regarding the implantation of bioprostheses in such patients. The haemodynamic advantages of stentless aortic bioprostheses support their use; however, these have not been studied yet in end-stage renal disease patients. We studied accordingly the early and mid-term outcomes of aortic valve replacement (AVR) using Medtronic Freestyle stentless aortic bioprostheses in this subset of patients in comparison with stented aortic bioprostheses.
    Full-text · Article · Jan 2016 · Interactive Cardiovascular and Thoracic Surgery
  • Source
    • "5-year survival in the mechanical valve replacement group was 52 ± 12.9% while in the bioprosthesis valve replacement group, it was 21.9 ± 7.1% (P = 0.0299) There is no difference in freedom from complication and structural valve deterioration between both groups. Therefore, bioprostheses should be considered Filsoufi et al. (2008) "
    [Show abstract] [Hide abstract]
    ABSTRACT: A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether a mechanical or bioprosthetic valve is superior for immediate and long-term survival in patients with end-stage renal disease (ESRD) undergoing a valve replacement. Altogether more than 150 papers were found using the reported search; of which, eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. There were no randomized controlled trials addressing the question. There was one systematic review and meta-analysis. All the other evidence was in the form of retrospective studies. The papers show that there is no significant difference in the results and survival between patients receiving a mechanical and those receiving a bioprosthetic valve. This was seen in the meta-analysis as well as the larger series of patients who underwent valve replacement. Bleeding complications were more common with mechanical valves. We conclude that the choice of valve for patients with ESRD should be determined by age, level of activity and patient choice. Due to the limited life expectancy of these patients, bioprosthetic valves should be considered, especially since there is no evidence of early degeneration of tissue valves in this subgroup of patients.
    Full-text · Article · May 2012 · Interactive Cardiovascular and Thoracic Surgery
  • [Show abstract] [Hide abstract]
    ABSTRACT: A beam of neutrons with an identical and well-known wavelength was produced by Bragg reflection in a perfect silicon crystal; the velocity of the neutrons was measured using a very precise time-of-flight method. According to the de Broglie equation, the product of these two quantities is equal to the quotient h/m<sub>n</sub> (h Planck constant, m<sub>n</sub> neutron mass). The result is h/m<sub>n</sub>=3 956 033 320(302)×10<sup>7</sup> m<sup>2</sup> s<sup>-1</sup> (relative uncertainty: 7.7×10<sup>-8</sup>). From this value, a value of the fine-structure constant α was derived, leading to α<sup>-1 </sup>=137 036 011 28(5 24) (relative uncertainty: 3.9×10<sup>-8 </sup>). The experiment was carried out at the high-flux reactor of the Institut Laue-Langevin in Grenoble, France
    No preview · Article · May 1995 · IEEE Transactions on Instrumentation and Measurement
Show more